Frontier Science collaborated with Janssen Actelion on the TOMORROW trial. The study assessed the efficacy, safety and pharmacokinetics of macitentan (Opsumit®) versus standard of care in children with pulmonary arterial hypertension (PAH).

Frontier Science (Scotland) Ltd worked on the output development and led statistical programming up to the dummy run preparing for formal protocol analyses. FSS was responsible for routine reporting and continues to be responsible for aggregate outputs for the Independent Data Monitoring Committee Open Session meetings. The statistical team in the Frontier Science Foundation office in Madison WI is a separate, firewalled, statistical unit providing unblinded statistical analysis for the IDMC.

OTHER PROJECTS

HERA

HERA

The HERA trial influenced changes in the standard of care for those with HER2-positive breast cancer. Find out more about the study design and our involvement >>

EPoS

EPoS

The EPoS (European Polyp Surveillance) study is a group of related randomised controlled clinical trials which aim to address the optimum colonoscopy surveillance interval for patients who have had premalignant polyps identified and removed from the large bowel, in...

NordICC

NordICC

Colorectal cancer (CRC) is major burden in western countries which develops over a long time-interval from precursor lesions which exist in the colon. Colonoscopy can detect and remove the precursor lesions and may therefore be an effective intervention for the...

WORK WITH US

Frontier Science Scotland provides adaptable solutions across data management and biostatistics for clinical trials. To find out more, get in touch.

data management

biostatistics

quality